Clinical Profile of Patients With MASLD in Kazakhstan and Clinical Effectiveness of Ursosan in Almaty
Eligible age
18–65 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study will look at the health characteristics of adults with metabolic dysfunction-associated steatotic liver disease (MASLD) in Kazakhstan. Researchers want to better understand how this liver condition appears in people in Kazakhstan and how it is managed in everyday medical care. About 420 adults with MASLD will take part. Researchers will collect information from their medical records, laboratory tests, liver imaging, and questionnaires. A smaller group of about 65 participants in Almaty who were already prescribed Ursosan® by their doctor before joining the study will be followed for 6 months. Researchers will look at changes in a liver enzyme called alanine aminotransferase (ALT) and other measures of liver health. The study does not assign Ursosan® or any other treatment. Treatment decisions are made by each participant's doctor as part of their usual medical care. The results may help researchers better understand MASLD in Kazakhstan and how people with MASLD respond to Ursosan® when it is used in everyday medical care.
Sponsor: Kazakh Association of Internal Medicine Specialists
You may qualify if…
- ✓ 3\. Imaging-confirmed hepatic steatosis based on ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI).
- ✓ 4\. At least one confirmed criterion of metabolic dysfunction-associated steatotic liver disease (MASLD), according to the EASL 2024 diagnostic criteria, including:
- ✓ Obesity or overweight:
- ✓ Body mass index ≥25 kg/m² (≥23 kg/m² in people of Asian ethnicity);
- ✓ Waist circumference ≥94 cm in men and ≥80 cm in women of European ethnicity, or ≥90 cm in men and ≥80 cm in women of Asian ethnicity;
- ✓ Hyperglycemia or type 2 diabetes mellitus:
- ✓ Prediabetes: HbA1c 39-47 mmol/mol (5.7-6.4%), or fasting plasma glucose 5.6-6.9 mmol/L (100-125 mg/dL), or 2-hour plasma glucose during an oral glucose tolerance test 7.8-11.0 mmol/L (140-199 mg/dL); or
- ✓ Type 2 diabetes mellitus: HbA1c ≥48 mmol/mol (≥6.5%), or fasting plasma glucose ≥7.0 mmol/L (≥126 mg/dL), or 2-hour plasma glucose during an oral glucose tolerance test ≥11.1 mmol/L (≥200 mg/dL), or treatment for type 2 diabetes mellitus;
You may not qualify if…
- ✕ 2\. Wilson disease, hypobetalipoproteinemia, lysosomal acid lipase deficiency, celiac disease, hemochromatosis, or cryptogenic hepatic steatosis, based on medical history.
- ✕ 3\. Autoimmune liver diseases, including primary biliary cholangitis (PBC), autoimmune hepatitis (AIH), primary sclerosing cholangitis (PSC), etc., based on medical history.
- ✕ 4\. Lipodystrophy, based on medical history. 5. Endocrine disorders, including growth hormone deficiency and primary or secondary panhypopituitarism, based on medical history.
- ✕ 6\. Nutritional deficiency or malnutrition. 7. Parenteral nutrition. 8. Bariatric surgery. 9. Anorexia. 10. Pregnancy. 11. Polycystic ovary syndrome. 12. Type 1 diabetes mellitus. 13. Hypothyroidism. 14. Chronic dialysis. 15. Active malignancy at the time of study enrollment. 16. Signs of psychiatric disorders. 17. Inability to comply with the study protocol or any other reason that, in the investigator's opinion, may prevent successful participation in the study.
Source: ClinicalTrials.gov · NCT07889999 · last updated 2026-10-22